1Novak J,Julian BA,Tomana M. IgA glycosylation and IgA immune complexes in the pathogenesis of lgA nephropathy[J].Seminars in Nephrology,2008.78-87.
2Barratt J,Feehally J,Smith AC. Pathogenesis of IgA nephropathy[J].Seminars in Nephrology,2004.197-217.
3Suzuki K,Honda K,Tanabe K. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan[J].Kidney International,2003.2286-2294.
4Suzuki H,Fan R,Zhang Z. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity[J].Journal of Clinical Investigation,2009.1668-1677.
5Berger J,Hinglais N. Intercapillary deposits of IgA-IgG[J].JOURNAL D' UROLOGIE ET DE NEPHROLOGIE(Paris),1968.694-695.
6Cattran DC,Coppo R,Cook HT. The Oxford classification of IgA nephropathy:rationale,clinicopathological correlations,and classification[J].Kidney International,2009.534-545.
7Shi SF,Wang SX,Jiang L. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy:validation of the Oxford classification[J].Clin J Am Soc Nephrol,2011.2175-2184.
8Coppo R,Peruzzi L,Amore A. IgACE:a placebo-controlled,randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgAN and moderate proteinuria[J].Journal of the American Society of Nephrology,2007.1880-1888.
9Li PKT,Leung CB,Chow KM. Hong Kong study using Valsartan in IgAN (HKVIN)-a double-blind randomized placebo-controlled study[J].American Journal of Kidney Diseases,2006.751-760.
10Praga M,Gutierrez E,Gonzalez E. Treatment of IgAN with ACE inhibitors:A randomized and controlled trial[J].Journal of the American Society of Nephrology,2003.1578-1583.
